Conference
A first-in-class, first-in-human phase I trial of KPT-330 (selinexor), a selective inhibitor of nuclear export (SINE) in patients (pts) with advanced solid tumors.
Authors
Mau-Soerensen M; Razak ARA; Shields AF; Gabrail NY; Gerecitano JF; Shacham S; Lassen UN; Rashal T; Cooksey J; Landesman Y
Volume
32
Pagination
pp. 2537-2537
Publisher
American Society of Clinical Oncology (ASCO)
Publication Date
May 20, 2014
DOI
10.1200/jco.2014.32.15_suppl.2537
Conference proceedings
Journal of Clinical Oncology
Issue
15_suppl
ISSN
0732-183X